3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Colorectal Neoplasms
15
Rectal Neoplasms
4
Pancreatic Neoplasms
3
Colonic Neoplasms
3
Esophageal Squamous Cell Carcinoma
2
Cholangiocarcinoma
2
Biliary Tract Neoplasms
2
Stomach Neoplasms
1
Rhabdomyosarcoma
1
Rare Tumour
1
Pathologic Complete Response
1
Pancreatic Cancer Resectable
1
Neoplasms, Second Primary
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Medulloblastoma
1
Lung Neoplasms
1
Locally Advanced Low Rectal Adenocarcinoma
1
Esophageal Neoplasms
1
Cirrhosis, Familial, with Pulmonary Hypertension
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Neuroendocrine
1
CRC
1
Biliary Cancer Metastatic
1
Appendiceal Neoplasms
1
Advanced Malignant Neoplasm
1
Advanced Esophageal Carcinoma
1
Interventions
blinatumomab
2
venetoclax
1
osimertinib
1
Vincristine
1
Transplantation
1
Sorafenib
1
Radiotherapy
1
Oxaliplatin
1
Neoadjuvant Therapy
1
N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide
1
Methotrexate
1
Maintenance
1
Liquid Biopsy
1
Leucovorin
1
Irinotecan
1
Hematologic Tests
1
Fluorouracil
1
Dexamethasone
1
Cytarabine
1
Cyclophosphamide
1
Chemotherapy, Adjuvant
1
Blood Specimen Collection
1
BEBT-908
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Not yet recruiting
×
Neoplasm, Residual
×
Irinotecan
×
Clear all
NCT05427669
2022-10-07
AFFORD
Sun Yat-sen University
Phase 3
Not yet recruiting
340 enrolled